Featured_Clinical_Trials | Vanderbilt-Ingram Cancer Center

Clinical study tests drug that may prevent cancer metastasis

Read more about Clinical study tests drug that may prevent cancer metastasis

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

Combination therapy improves small-cell lung cancer survival

Read more about Combination therapy improves small-cell lung cancer survival

Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.

October 25, 2023

VUMC to help engage more study participants in research decisions

Human research will be more equitable, inclusive and stronger if the people who are participants in studies also help plan and guide the direction of those studies.

November 17, 2023

Tumor antigens key to improving cancer immunotherapy study

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.

November 17, 2023

Vanderbilts Dr. W. Kimryn Rathmell to be appointed director of the National Cancer Institute

Kimryn Rathmell MD PhD MMHC the Hugh Jackson Professor of Medicine and chair of the Department of Medicine at Vanderbilt University Medical Center will be appointed Director of the National Cancer Institute.

Study to test combination therapy for breast cancer

Read more about Study to test combination therapy for breast cancer

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

Study seeks to ease ‘chemobrain’ for cancer patients

Read more about Study seeks to ease ‘chemobrain’ for cancer patients

Many women who receive chemotherapy for breast cancer report problems with their thinking, memory and attention after treatment. And as the survival rates for breast cancer increase, so do these issues associated with chemotherapy. Paul Newhouse, M.

VICC treats first patient in Tennessee with novel cellular immunotherapy

Read more about VICC treats first patient in Tennessee with novel cellular immunotherapy

For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]

VICC trial putting lung cancer therapy to the test

Read more about VICC trial putting lung cancer therapy to the test

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. That head injury may have […]

Horn to lead lung cancer combination therapy trial

Read more about Horn to lead lung cancer combination therapy trial

Leora Horn, M.D., M.

New prostate cancer therapy investigated at VUMC

Read more about New prostate cancer therapy investigated at VUMC

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Investigators, David Penson, M.D.

Subscribe to Featured_Clinical_Trials